Insider buying last 90 days
No open-market insider purchases were filed for TVTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TVTX insider filing, plotted on the chart in Gekko.Open TVTX in Gekko
NASDAQ: TVTX
Travere Therapeutics (TVTX) Stock Analysis & Forecast
Sep 28 close
$61.57+2.13 (+3.6%)
Gekko Brief
AI summaryTravere Therapeutics this week is dominated by a leadership transition and patent news for FILSPARI. President and CEO Eric Dube will step down effective 1 December 2026, with Bradley Campbell, former CEO of Amicus Therapeutics, named as successor. Alongside this, the U.S. Patent and Trademark Office issued a Notice of Allowance covering methods of using FILSPARI (sparsentan) in focal segmental glomerulosclerosis, extending protection into October 2037. Shares also gapped down intraweek, moving from a prior close of $62.86 to an open of $60.37.
TVTX closed at $61.57, up 3.6%, sitting between its 50-day average of $62.10 and 200-day average of $44.53. The GekkoIndex reads 62.1, placing the stock in the Accumulation zone. Price stands 8.5% below the Gekko Fair Value estimate of $67.28. One-year return stands at 150.2%, while the one-month return is -8.8%.
The next earnings report is scheduled for 29 October 2026 after the close, 30 days out and beyond a typical 20-trading-day window; the prior report on 4 August 2026 showed an EPS of -0.37 against a -0.14 estimate, with a 14.2% reaction. Smart-money and options activity show no recorded insider, Congress, or unusual options signals in their respective windows, and one trailblazer holder is noted. Analyst consensus stands at 11 buys, 1 hold, and 0 sells among 12 firms, with a consensus target of $75.21. Seasonally, the next 20 trading days have averaged +5.1% over 5 years, rising in 3 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Travere Therapeutics price vs fair value
Close $61.57200-day averageGekko Fair Value $67.28
Travere Therapeutics quick facts
- Market cap
- $5.73B
- P/E ratio
- —
- Forward P/E
- 39.8
- EPS, TTM
- −$0.74
- Revenue, TTM
- $591.3M
- Profit margin
- -7.3%
- Dividend yield
- —
- Beta
- 1.06
- Volume
- 1.22M avg 1.54M
- 1-year return
- +150.2%
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±10.8%
- 50-day average
- $62.10
- 200-day average
- $44.53
- Next earnings
- Oct 29 after close
- Shares outstanding
- 94.26M
Travere Therapeutics swing-trade checklist
Travere Therapeutics scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $61.57 sits between the 50-day ($62.10) and 200-day ($44.53) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
62.1, Accumulation
Reading 62.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
8.5% below
Price is 8.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Oct 29, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.1% on average
From this point in the calendar, the next 20 trading days averaged +5.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Travere Therapeutics stock chart and price history
Travere Therapeutics closed at $61.57 on Sep 28, 2026, +150.2% over the past year, inside a 52-week range of $22.06 to $68.73.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −8.8%
- 3 months
- +5.6%
- 6 months
- +125.9%
- 1 year
- +150.2%
The full TVTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TVTX in Gekko
Follow Travere Therapeutics through every session
Put TVTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TVTX in GekkoFree for 7 days. No credit card required.
About Travere Therapeutics
Travere Therapeutics focuses on treatments for rare conditions affecting the kidneys and metabolism. Its best-known product is FILSPARI, an oral, once-daily medicine that works against two biological pathways linked to disease progression and has been approved to slow kidney decline in adults with primary IgA nephropathy at risk of worsening, and later cleared to reduce proteinuria in patients eight and older with focal segmental glomerulosclerosis without nephrotic syndrome, a condition for which it stands as the only approved medicine of its kind.
Beyond FILSPARI, the company sells Thiola and Thiola EC, tiopronin tablets used to treat cystinuria, a genetic disorder that causes repeated kidney stones. It is also developing pegtibatinase, an experimental enzyme replacement therapy aimed at classical homocystinuria, which remains in its pipeline rather than on the market. Its customers are patients and physicians treating these rare inherited and progressive diseases.
The company was previously known as Retrophin, Inc. before adopting the Travere name in November 2020. It is based in San Diego, California, and incorporated in Delaware. Travere Therapeutics is listed on the NASDAQ under the ticker TVTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- travere.com
Travere Therapeutics GekkoIndex: the smart money zone
Travere Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.1, in the Accumulation zone, up 2.3 points over five sessions.
62.1Accumulation
Up 2.3 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 25 | −0.4% | +17.5% | ||
| Accumulation (current zone) | 166 | +1.5% | +5.9% | ||
| Neutral | 425 | +1.9% | +8.3% | ||
| Distribution | 52 | +3.4% | +8.1% | ||
| Selling | 4 | Too few readings yet | |||
Average TVTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the TVTX price, zone by zone.Track TVTX in Gekko
Is Travere Therapeutics stock overvalued? Gekko Fair Value
Travere Therapeutics trades 8.5% below Gekko Fair Value of $67.28, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Travere Therapeutics shares are worth, recalculated every trading day.
$67.28
Gekko Fair Value, Sep 26, 2026
8.5% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open TVTX in Gekko
Travere Therapeutics insider and Congress trading
No open-market insider purchases were filed for Travere Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TVTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TVTX, plotted on the chart in Gekko.Open TVTX in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds TVTX.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Travere Therapeutics earnings: next date and track record
Travere Therapeutics reports on Oct 29, 2026, after the close (30 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 30 days away
- EPS estimate
- $0.03
- Revenue estimate
- $195.7M
4 of 8reports beat the EPS estimate
±6.5%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Travere Therapeutics reported record Q2 2026 U.S. revenue of $141 million for FILSPARI, driven by over 2,000 new patient start forms across IgA nephropathy and FSGS. IgA nephropathy demand grew quarter-over-quarter despite new market entrants, while the FSGS launch exceeded management expectations. The company also secured a USPTO Notice of Allowance for a sparsentan patent and closed an exclusive licensing deal for civorebrutinib.
- Guidance
- Management enters H2 2026 from a position of strength, with FILSPARI momentum across two indications. Pegtibatinase pivotal Phase III data is expected next year, positioning it as the pipeline's next potential commercial asset.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.37 est −$0.14 | $169.6M est $157.3M | +14.2% |
| May 4, 2026 | $0.05 est −$0.06 | $127.2M est $136.2M | +1.5% |
| Feb 19, 2026 | $0.03 est $0.03 | $129.7M est $144.6M | +9.0% |
| Oct 30, 2025 | $0.28 est −$0.31 | $164.9M est $147.0M | +17.3% |
| Aug 6, 2025 | $0.13 est $0.04 | $114.4M est $99.55M | +1.4% |
| May 1, 2025 | −$0.19 est −$0.39 | $81.73M est $88.80M | +1.6% |
| Feb 20, 2025 | −$0.47 est −$0.38 | $74.79M est $72.38M | −5.8% |
| Oct 31, 2024 | −$0.70 est −$0.68 | $62.90M est $71.44M | −1.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Travere Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Travere Therapeutics is $75.21, +22.2% from the last close, from 12 firms rating the stock in the last 90 days.
$75.21consensus 12-month target, +22.2% from the last close
Now $61.57Avg $75.21
Low $62High $90
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | H.C. Wainwright | $67 | +8.8% |
| Sep 23 | Bank of America Securities | $71 | +15.3% |
| Sep 23 | Guggenheim | $89 | +44.6% |
| Sep 22 | H.C. Wainwright | $67 | +8.8% |
| Sep 22 | Wedbush | $76 | +23.4% |
+5.9%average 20-day move after past Accumulation readings
+5.1%average move over the next 20 trading days in the last 5 years
±4.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Travere Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Travere Therapeutics averaged +5.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.8% | 4 of 5 |
| Next 10 trading days | +0.9% | 3 of 5 |
| Next 15 trading days | +3.7% | 3 of 5 |
| Next 20 trading days | +5.1% | 3 of 5 |
| Next 30 trading days | +12.1% | 3 of 5 |
For scale, TVTX’s typical 20-trading-day move in either direction is about 10.8%.
Travere Therapeutics market cap and key statistics
Travere Therapeutics’s market cap is $5.73B and revenue of $591.3M over the last twelve months.
Valuation
- Market cap
- $5.73B
- Forward P/E
- 39.8
- EPS, TTM
- −$0.74
- Gekko Fair Value
- $67.28
Trading
- Volume
- 1.22M
- Avg volume, 20 days
- 1.54M
- 52-week high
- $68.73
- 52-week low
- $22.06
- Shares outstanding
- 94.26M
Financials
- Revenue, TTM
- $591.3M
- Profit margin
- -7.3%
- Return on equity
- -236.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.06
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±10.8%
Travere Therapeutics stock news this week
Coverage of Travere Therapeutics this week reads positive: 7 positive, 1 neutral and 3 negative headlines.
- CEO Change Could Be A Key Moment For Travere Therapeutics Stock (TVTX)Simply Wall Street, Sep 25
- Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Time to Sell?Defense World, Sep 24
- Travere Therapeutics appoints new CEO Bradley CampbellThe Globe and Mail, Sep 23
- Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARIYahoo Finance, Sep 23
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental GlomerulosclerosisBioSpace, Sep 23
- Travere receives patent allowance for FILSPARI use in FSGSInvesting.com, Sep 23
Travere Therapeutics peers
Travere Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Travere Therapeutics stock FAQ
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $5.73B at the Sep 28, 2026 close of $61.57, with 94.26M shares outstanding.
What is the Travere Therapeutics stock forecast?
The consensus analyst 12-month price target for Travere Therapeutics is $75.21, +22.2% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Travere Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Travere Therapeutics is undervalued: the Sep 28, 2026 close of $61.57 is 8.5% below Gekko Fair Value of $67.28. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Travere Therapeutics report earnings next?
Travere Therapeutics is expected to report on Oct 29, 2026, after the market closes (30 days away). Analysts expect earnings of $0.03 per share on revenue of $195.7M. Travere Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 6.5% on average across the report.
What is Travere Therapeutics’s 52-week high and low?
Travere Therapeutics’s 52-week high is $68.73 and its 52-week low is $22.06; it closed at $61.57 on Sep 28, 2026, +150.2% over the past year.
Is Travere Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Travere Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.